Assaf Oron sold $4,072 of HLSQ
Chief Business Officer at BiomX Inc.. 10,914 shares at an average of $0.37, traded Nov 29, 2023, filed Dec 1, 2023.
Score components
- +15RoleOfficer
- 0Trade size$4k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +8.5%, 3m -17.4%, 6m +55.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001213900-23-092074, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 29, 2023 | SOpen-market sale Common Stock | -5,444 | $0.40 | $2,178 | 5,470 | Dec 1, 2023 |
| Nov 29, 2023 | SOpen-market sale Common Stock | -3,414 | $0.35 | $1,195 | 2,056 | Dec 1, 2023 |
| Nov 29, 2023 | SOpen-market sale Common Stock | -2,056 | $0.34 | $699 | 0 | Dec 1, 2023 |
Related signals
Other insiders at BiomX Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 60Notable | HLSQsell BiomX Inc. | Reuven Yeganeh director, owner | $4.9M 980,000 shares | -218% | |
| 60Notable | HLSQsell BiomX Inc. | Reuven Yeganeh director, owner | $3.4M 670,000 shares | -223% | |
| 12Weak | HLSQsell BiomX Inc. | OrbiMed Israel BioFund GP Limited Partnership owner | $9,280 24,344 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.